OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.…
OmniAb (OABI) Q3 Results Keep Cash Progress In Focus
OmniAb (NASDAQ: OABI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 89 employees.
The shares were at 4.660 USD on 20 November 2026, up 237.7% over 52 weeks. Its 52-week range is 1.350 USD to 5.450 USD: the price is 14.5% below the high and 245.2% above the low.
Its market capitalisation is 679.71M USD.
OmniAb reports return on equity of -24.3%, an operating margin of -92.9% and revenue up 78.3% year over year.
It holds more cash than debt, a net cash position of 46.07M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 6 analysts cover the stock; their mean price target of 8.333 USD is 78.8% above the current price. The next earnings report is expected on 4 March 2027.